Home/Filings/4/0001104659-24-030156
4//SEC Filing

Ali Asif 4

Accession 0001104659-24-030156

CIK 0001377121other

Filed

Feb 29, 7:00 PM ET

Accepted

Mar 1, 8:45 PM ET

Size

14.5 KB

Accession

0001104659-24-030156

Insider Transaction Report

Form 4
Period: 2024-02-29
Ali Asif
Chief Financial Officer
Transactions
  • Sale

    Common Stock

    2024-02-29$30.61/sh7,850$240,28942,734 total
  • Sale

    Common Stock

    2024-02-29$31.00/sh2,089$64,75940,645 total
  • Exercise/Conversion

    Common Stock

    2024-03-01$12.17/sh+12,000$146,04052,645 total
  • Sale

    Common Stock

    2024-03-01$32.22/sh12,000$386,64040,645 total
  • Sale

    Common Stock

    2024-03-01$32.33/sh2,248$72,67838,397 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2024-03-0112,00051,750 total
    Exercise: $12.17Exp: 2033-01-15Common Stock (12,000 underlying)
Footnotes (4)
  • [F1]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $30.57 to $30.76. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  • [F2]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $32.17 to $32.31. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  • [F3]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $32.28 to $32.39. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  • [F4]The stock option was granted to the Reporting Person on January 16, 2023 and vests in 48 equal monthly installments following the date of grant.

Issuer

Protagonist Therapeutics, Inc

CIK 0001377121

Entity typeother

Related Parties

1
  • filerCIK 0001921163

Filing Metadata

Form type
4
Filed
Feb 29, 7:00 PM ET
Accepted
Mar 1, 8:45 PM ET
Size
14.5 KB